Breast Cancer and Tamoxifen: A Nigerian Perspective to Effective Personalised Therapy

QR Code

Breast Cancer and Tamoxifen: A Nigerian Perspective to Effective Personalised Therapy

Ayorinde Adehin,1,2 Martin Alexander Kennedy,3 Julius Olugbenga Soyinka,1 Olusegun Isaac Alatise,4 Olalekan Olasehinde,4 Oluseye Oladotun Bolaji1 1Department of Pharmaceutical Chemistry, Faculty of Pharmacy, Obafemi Awolowo University, Ile-Ife, Nigeria; 2Institute of Biomedical and Pharmaceutical Sc...

Description complète

Enregistré dans:

Détails bibliographiques
Auteurs principaux:	Adehin A, Kennedy MA, Soyinka JO, Alatise OI, Olasehinde O, Bolaji OO
Format:	article
Langue:	EN
Publié:	Dove Medical Press 2020
Sujets:	breast cancer estrogen receptor tamoxifen nigeria epigenetics genomics Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282
Accès en ligne:	https://doaj.org/article/de3ee25b2dc741d083b7773d4bf14d99
Tags:	Ajouter un tag Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires

Tumor suppressor ING4 inhibits estrogen receptor activity in breast cancer cells
par: Keenen MM, et autres
Publié: (2016)

Evaluating the Risk of Breast Cancer Recurrence and Metastasis After Adjuvant Tamoxifen Therapy by Integrating Polymorphisms in Cytochrome P450 Genes and Clinicopathological Characteristics
par: Hui Pang, et autres
Publié: (2021)

Design and Characterization of Maltoheptaose-<i>b</i>-Polystyrene Nanoparticles, as a Potential New Nanocarrier for Oral Delivery of Tamoxifen
par: Marcos Antonio Villetti, et autres
Publié: (2021)

Cost-effectiveness of Tamoxifen, Aromatase Inhibitor, and Switch Therapy (Adjuvant Endocrine Therapy) for Breast Cancer in Hormone Receptor Positive Postmenopausal Women in India
par: Butani D, et autres
Publié: (2021)

Dietary Supplement Use and Interactions with Tamoxifen and Aromatase Inhibitors in Breast Cancer Survivors Enrolled in Lifestyle Interventions
par: Maura Harrigan, et autres
Publié: (2021)

Terapia médica de la ginecomastia con tamoxifeno. Influencia del volumen y duración de la ginecomastia en el resultado terapéutico
par: Devoto C,Enzo, et autres
Publié: (2007)

Neighborhood disadvantage and individual-level life stressors in relation to breast cancer incidence in US Black women
par: Lauren E. Barber, et autres
Publié: (2021)

Discordance of the estrogen receptor and HER-2/neu in breast cancer from primary lesion to first and second metastatic site
par: Lower EE, et autres
Publié: (2017)

Effects of CYP2D6 and CYP3A5 polymorphisms on tamoxifen and its metabolites in Thai breast cancer patients
par: Charoenchokthavee W, et autres
Publié: (2017)

Profiling of gene expression regulated by 17β-estradiol and tamoxifen in estrogen receptor-positive and estrogen receptor-negative human breast cancer cell lines
par: Rangel N, et autres
Publié: (2017)

Survival rates of advanced estrogen-receptor positive breast cancer. Analysis of 211 cases
par: Sánchez,César, et autres
Publié: (2020)

Assessment of changes in the brca2 and p53 genes in breast invasive ductal carcinoma in northeast Brazil
par: Ramalho,Eduardo AVF, et autres
Publié: (2014)

Prognostic Significance of CSF-1R Expression in Early Invasive Breast Cancer
par: Nazia Riaz, et autres
Publié: (2021)

Application of preoperative ultrasound features combined with clinical factors in predicting HER2-positive subtype (non-luminal) breast cancer
par: Jin Zhou, et autres
Publié: (2021)

Prevalence of CYP2D6*2, CYP2D6*4, CYP2D6*10, and CYP3A5*3 in Thai breast cancer patients undergoing tamoxifen treatment
par: Charoenchokthavee W, et autres
Publié: (2016)

Estrogen receptor variant ERα46 and insulin receptor drive in primary breast cancer cells growth effects and interleukin 11 induction prompting the motility of cancer‐associated fibroblasts
par: Francesca Cirillo, et autres
Publié: (2021)

Terapia endocrina neoadyuvante en cáncer de mama, una alternativa de tratamiento e investigación
par: Acevedo,Francisco, et autres
Publié: (2013)

Interleukin-6 is a potential therapeutic target in interleukin-6 dependent, estrogen receptor-α-positive breast cancer
par: Casneuf T, et autres
Publié: (2016)

Analyzing the Estrogen Receptor Status of Liver Metastases with [<sup>18</sup>F]-FES-PET in Patients with Breast Cancer
par: Jorianne Boers, et autres
Publié: (2021)

Protein expression profile and microRNA expression signature in estrogen receptor-positive and -negative breast cancers: report of two cases
par: Tsunoda Y, et autres
Publié: (2018)

NOTTINGHAM PROGNOSTIC INDEX IN DIFFERENT AGE GROUPS OF NEWLY DIAGNOSED BREAST CARCINOMA PATIENTS AND ITS ASSOCIATION WITH ER, PR AND HER-2-NEU RECEPTOR STATUS
par: Faryal Zafar, et autres
Publié: (2019)

Association of Endocrine Therapy and Dementia in Women with Breast Cancer
par: Thompson MR, et autres
Publié: (2021)

Positive Regulation of Estrogen Receptor Alpha in Breast Tumorigenesis
par: Lucas Porras, et autres
Publié: (2021)

PGRMC1 Promotes Progestin-Dependent Proliferation of Breast Cancer Cells by Binding Prohibitins Resulting in Activation of ERα Signaling
par: Yingxue Bai, et autres
Publié: (2021)

¿Es curable el cáncer de mama en etapa precoz?: Resultados del tratamiento combinado con cirugía, radioterapia y quimioterapia
par: Sánchez R,César, et autres
Publié: (2007)

Tamoxifeno y antidepresivos: ¿Antagonistas en la prevención del cáncer de mama?
par: IRARRÁZAVAL O,MARÍA ELISA
Publié: (2011)

Proteolysis-targeting chimeras and their implications in breast cancer
par: Angeles C. Tecalco-Cruz, et autres
Publié: (2021)

Towards Unravelling the Role of ERα-Targeting miRNAs in the Exosome-Mediated Transferring of the Hormone Resistance
par: Olga E. Andreeva, et autres
Publié: (2021)

UK Women’s Views of the Concepts of Personalised Breast Cancer Risk Assessment and Risk-Stratified Breast Screening: A Qualitative Interview Study
par: Charlotte Kelley-Jones, et autres
Publié: (2021)

In vivo and in vitro estrogenic and progestagenic actions of Tibolone
par: SADARANGANI,ANIL, et autres
Publié: (2005)

ASSOCIATION OF HORMONE RECEPTORS WITH RISK FACTORS AMONG BREAST CANCER PATIENTS
par: Ummara Aslam, et autres
Publié: (2021)

Nomogram for the personalisation of radiotherapy treatments in breast cancer patients
par: Inmaculada Beato Tortajada, et autres
Publié: (2021)

Hypoxia-inducible factor-1α expression and breast cancer recurrence in a Danish population-based case control study
par: Lindsay J. Collin, et autres
Publié: (2021)

Endocrine Treatment for Breast Cancer Patients Revisited—History, Standard of Care, and Possibilities of Improvement
par: Naiba Nabieva, et autres
Publié: (2021)

Diagnostic Performance of [<sup>18</sup>F]FDG PET in Staging Grade 1–2, Estrogen Receptor Positive Breast Cancer
par: Ramsha Iqbal, et autres
Publié: (2021)

Centchroman versus Tamoxifen in the management of mastalgia: a randomized controlled clinical trial
par: S Khadka, et autres
Publié: (2016)

Intracellular aggregated TRPV1 is associated with lower survival in breast cancer patients
par: Lozano C, et autres
Publié: (2018)

Preparation, Characterization, and Pharmacokinetic Study of a Novel Long-Acting Targeted Paclitaxel Liposome with Antitumor Activity
par: Han B, et autres
Publié: (2020)

CYP2D6 polymorphisms may predict occurrence of adverse effects to tamoxifen: a preliminary retrospective study
par: Wickramage I, et autres
Publié: (2017)

The effects of turmeric (curcumin) on tumor suppressor protein (p53) and estrogen receptor (ERα) in breast cancer cells
par: Hallman K, et autres
Publié: (2017)